Sutro Biopharma, Inc.
STRO
Rank in Stocks
#17230
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the... Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Share Price
$10.61
Last synced: 2026-11-09
Market Cap
$175.93M
Change (1 day)
10.29%
Change (1 year)
30.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sutro Biopharma, Inc. (STRO)
Category
Healthcare
Number of shares outstanding for Sutro Biopharma, Inc. (STRO)
Number of shares outstanding as of June 2026: 16.57M
According to Sutro Biopharma, Inc.'s latest financial reports, its current number of shares outstanding is 16.57M. At the end of 2025 the company had 8.50M shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for Sutro Biopharma, Inc. (STRO) from 2016 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 16.57M | 95.01% |
| 2025 | 8.50M | 10.61% |
| 2024 | 7.68M | 27.70% |
| 2023 | 6.02M | 18.57% |
| 2022 | 5.07M | 10.02% |
| 2021 | 4.61M | 41.58% |
| 2020 | 3.26M | 41.88% |
| 2019 | 2.30M | 0.45% |
| 2018 | 2.29M | 226.65% |
| 2017 | 699.74K | 1,485.99% |
| 2016 | 44.12K | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.50M | 1,429.73% |
US
|
|
| 401.00M | 2,319.80% |
US
|
|
| 478.91M | 2,789.96% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.74M | 278.57% |
NL
|
Questions about Sutro Biopharma, Inc.'s number of shares outstanding
What is Sutro Biopharma, Inc.'s number of shares outstanding?
Sutro Biopharma, Inc.'s number of shares outstanding is 16.57M, as of Jun 2026.
What was Sutro Biopharma, Inc.'s number of shares outstanding in 2025?
In 2025, Sutro Biopharma, Inc.'s number of shares outstanding was 8.50M, 10.61% more than in 2024 (7.68M).
How has Sutro Biopharma, Inc.'s number of shares outstanding changed since 2020?
From 2020 to 2025, Sutro Biopharma, Inc.'s number of shares outstanding went from 3.26M to 8.50M, an average growth of 21.14% a year.